AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34787762
Drug: Conventional periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional periodontal treatment associated with 10 laser applications by the ILIB‐Modified (ILIB‐M) technique
Trial: 32532654
Drug: Ramelteon (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon (8 mg)
Trial: 36375174
Drug: Antipsychotics
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics
Trial: 32753699
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies against non-self glycans
Trial: 32753699
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies against self glycans
Trial: 39178051
Drug: Electroconvulsive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive Therapy (ECT)
Trial: 33907075
Drug: Non-Electroconvulsive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Electroconvulsive Therapy (non-ECT)
Trial: 33453383
Drug: Selenite-loaded chitosan
RxNorm normalized name: selenite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenite-loaded chitosan nanoparticles (SeChNPs) 1 g/kg diet
Trial: 33453383
Drug: Selenite-loaded chitosan
RxNorm normalized name: selenite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenite-loaded chitosan nanoparticles (SeChNPs) 2 g/kg diet
Trial: 33856434
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (topical ocular hypotensive medication)
Trial: 32779952
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 25 mg weekly
Trial: 32790845
Drug: rhTPO (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTPO (300 U/kg once daily from days 14 to 28 after UCBT)
Trial: 38942209
Drug: Cariprazine 1.5
RxNorm normalized name: cariprazine 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 1.5 mg/d
Trial: 37551609
Drug: Cariprazine 3
RxNorm normalized name: cariprazine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 3 mg/d
Trial: 32646561
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg every 2 weeks
Trial: 36048465
Drug: Temperature-Controlled Radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temperature-Controlled Radiofrequency (TCRF) device treatment of the nasal valve
Trial: 33023497
Drug: Interprofessional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interprofessional medication assessment
Trial: 35793990
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg
Trial: 35920686
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment
Trial: 34259467
Drug: Levonorgestrel 52‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 52‐mg intrauterine system
Trial: 34171293
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Care (conventional medical treatment)
Trial: 32104921
Drug: 2.45 GHz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.45 GHz Wi-Fi exposure with a total antenna input power of 220 mW; specific absorption rate (SAR) in cortical brain regions approximately 1-2 mW/kg.
Trial: 39249590
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (control group)
Trial: 32959557
Drug: Prednisone acetate
RxNorm normalized name: Prednisone acetate
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone acetate (30 mg/d for 5 days, then reduced to 10 mg/d for 1 week) and muscular injection with vitamin B12 (0.5 mg) and B1 (0.1 mg) daily, followed by oral vitamin B1 (10 mg, three times a day for 10 days).
Trial: 32356074
Drug: Sham CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham CPAP therapy
Trial: 35182035
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin capsule (ORMD‐0801) 8 mg
Trial: 35182035
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin capsule (ORMD‐0801) 48 mg
Trial: 35182035
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin capsule (ORMD‐0801) 8 mg (stage 2)
Trial: 35182035
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin capsule (ORMD‐0801) 32 mg (stage 2)
Trial: 35182035
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin capsule (ORMD‐0801) 48 mg (stage 2)
Trial: 35182035
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin capsule (ORMD‐0801) 8-48 mg (both stages)
Trial: 37858867
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy
Trial: 34481972
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet with additional extra virgin olive oil (40 mL daily) and pistachios (25 to 30 g daily)
Trial: 33098997
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of standard doses of FOLFOX/CAPOX
Trial: 33098997
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of standard doses of FOLFOX/CAPOX
Trial: 32388538
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg oral dose)
Trial: 33913765
Drug: Postpartum DMPA
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postpartum DMPA administration
Trial: 33913765
Drug: No DMPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No DMPA administration (Control)
Trial: 35609913
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment only
Trial: 32885541
Drug: E‐AR cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E‐AR cream containing GSH‐C4 (0.1%), beta‐Glycyrrhetic (0.5%), and azelaic acids (10%) applied daily for 8 weeks
Trial: 32885541
Drug: E‐AR cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E‐AR cream
Trial: 36307922
Drug: CETP inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CETP inhibitor TA-8995 (obicetrapib)
Trial: 32948577
Drug: Stem cell
RxNorm normalized name: Stem cells, apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem cell treatments
Trial: 35666852
Drug: Budesonide oral
RxNorm normalized name: budesonide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide oral suspension (BOS)
Trial: 33575846
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment (RT or RCT)
Trial: 33575846
Drug: Adjuvant radio(chemo)therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radio(chemo)therapy (RCT and RT)
Trial: 38368409
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant therapy
Trial: 39311825
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion
Trial: 33978187
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg elemental iron as ferrous sulfate for 12 weeks
Trial: 33637837
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TaU)
Trial: 33663545
Drug: Betaine supplementation
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine supplementation (2 g/day)
Trial: 35094931
Drug: Progressive tendon-loading
RxNorm normalized name: Bos taurus tendon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive tendon-loading exercise therapy
Trial: 35094931
Drug: Eccentric exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eccentric exercise therapy
Trial: 36205248
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg daily for 45 days
Trial: 35318115
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (administered at birth, 1 month, and 6 months)
Trial: 33330915
Drug: Leucine intake
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine intake ranging from 20 to 120 mg . kg‐1 . d‐1
Trial: 35709830
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of donor feces
Trial: 35709830
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g of donor feces
Trial: 32284450
Drug: Concurrent resistance-aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent resistance-aerobic training for 16 weeks, 60 min three times a week
Trial: 32959481
Drug: Internet-delivered cognitive-behavioural
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive-behavioural therapy (ICBT) with brief weekly telephone support
Trial: 32164773
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group doing their daily activities
Trial: 35287166
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch + mini‐lozenge
Trial: 35924071
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with a fixed injection flow rate of 3.5 ml/s, time was 12 s with a total of 42 ml.
Trial: 38776334
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy
Trial: 32732154
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (3,666 mg/day for 3 months)
Trial: 33423540
Drug: Warfarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin plus aspirin
Trial: 36151529
Drug: Training GPs
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training GPs to offer treatment as the default choice using an encounter decision aid (paper or electronic).
Trial: 33933894
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill
Trial: 35716471
Drug: Gyejibongnyeong-Hwan (GBH)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gyejibongnyeong-Hwan (GBH) treatment for 8 weeks
Trial: 35716471
Drug: Gyejibongnyeong-Hwan (GBH)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gyejibongnyeong-Hwan (GBH) treatment
Trial: 36349190
Drug: Ultrasound-guided lumbar
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided lumbar plexus block (group L)
Trial: 33188075
Drug: Sequential two-step
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential two-step cell-based assay measuring TNF-α production by CD14+16+ intermediate monocytes after EBV peptide stimulation
Trial: 33188075
Drug: Sequential cell-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential cell-based assay examining monocyte and eBm5 cell response to EBV peptides
Trial: 36389766
Drug: Anakinra (IL-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (IL-1 receptor antagonist)
Trial: 35031013
Drug: Gestational diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestational diabetes mellitus (GDM) treatment
Trial: 34310464
Drug: rAAV2/2‐ND4 gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV2/2‐ND4 gene therapy
Trial: 36063821
Drug: Asundexian 10
RxNorm normalized name: Asundexian
DrugBank: Asundexian (DB19088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asundexian 10 mg
Trial: 36063821
Drug: Asundexian 50
RxNorm normalized name: Asundexian
DrugBank: Asundexian (DB19088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asundexian 50 mg
Trial: 39546314
Drug: Intensive Home
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Home Treatment (IHT)
Trial: 36461619
Drug: THRIVE (100%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THRIVE (100% oxygen, 40 L/min)
Trial: 36461619
Drug: Facemask (100%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facemask (100% oxygen, 6 L/min)
Trial: 33068792
Drug: Androgen suppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen suppression for 6 months, starting either 4 months before or concurrently with definitive prostate radiation therapy
Trial: 37743037
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination therapy
Trial: 37792369
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin
Trial: 33922507
Drug: DHA-rich tuna
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich tuna oil capsules (6 capsules per day) for 8 weeks
Trial: 33922507
Drug: Placebo (Sunola
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Sunola oil) capsules (6 capsules per day) for 8 weeks
Trial: 36440464
Drug: Omalizumab 300
RxNorm normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab 300 mg
Trial: 32037784
Drug: Concurrent exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent exercise with post-activation potentiation (CE-PAP)
Trial: 32037784
Drug: Concurrent exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent exercise (CE)
Trial: 39324726
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy
Trial: 37174730
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Control)
Trial: 34582701
Drug: Yoga therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga therapy (asana and pranayama practice for 12 weeks)
Trial: 34582701
Drug: Oral antidiabetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antidiabetic drugs (OAD) alone
Trial: 32887762
Drug: Combined scatter
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined scatter correction (CC)
Trial: 35899371
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment control condition
Trial: 33743869
Drug: IgM antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM antibodies
Trial: 33743869
Drug: Neutralising antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralising antibodies over time
Trial: 33743869
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies over time
Trial: 35488213
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality (VR) and Motor Imagery (MI) in addition to Physical Therapy (PT)
Trial: 33579288
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (long-acting beta-2 agonist [LABA] or long-acting muscarinic antagonist [LAMA]) in GOLD III/IV group
Trial: 33579288
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy in GOLD III/IV group
Trial: 33579288
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy in GOLD I/II group
Trial: 32041441
Drug: Microneedling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling with topical tacrolimus at 2 weeks intervals for a maximum of 6 months
Trial: 32041441
Drug: Tacrolimus 0.1%
RxNorm normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.1% ointment applied once daily for 6 months
Trial: 32041441
Drug: Microneedling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling with topical tacrolimus
Trial: 32692071
Drug: Treatment effect
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effect reporting
Trial: 32107270
Drug: Daily sunscreen
RxNorm normalized name: ZINC OXIDE 220 mg in 1 mL TOPICAL CREAM [SPF 30 Daily Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sunscreen use (prevention)
Trial: 32792358
Drug: Immune-checkpoint-blockade (ICB)
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune-checkpoint-blockade (ICB) treatment
Trial: 35739094
Drug: BNT162b2 vaccine
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 vaccine (3 doses)
Trial: 33518304
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of VE and n-3 fatty acids
Trial: 32702891
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injection (1 mL of 0.5% bupivacaine and 10 mg of triamcinolone acetonide)
Trial: 32702891
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL of 0.5% bupivacaine and 1 mL of normal saline)
Trial: 32717295
Drug: 7 mg
RxNorm normalized name: pectin 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg transdermal nicotine
Trial: 34542418
Drug: Reminiscence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence therapy using VR in the form of head-mounted displays (HMDs)
Trial: 34542418
Drug: Reminiscence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence therapy using a laptop computer supplemented by physical items (active control)
Trial: 36111378
Drug: Dexmedetomidine 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.50 μg/kg
Trial: 36111378
Drug: Nalbuphine 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.08 mg/kg
Trial: 37962876
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy
Trial: 33586453
Drug: Pre-ICH antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-ICH antiplatelet therapy
Trial: 34233065
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitors (GPI)
Trial: 32172626
Drug: Individual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatment
Trial: 33994515
Drug: Home-visit occupational
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home-visit occupational therapy using Management Tool for Daily Life Performance (MTDLP)
Trial: 33994515
Drug: Home-visit occupational
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home-visit occupational therapy without using MTDLP (Control)
Trial: 33028623
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by interval debulking surgery (arm B)
Trial: 38052042
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG)
Trial: 33549429
Drug: Virgin coconut
RxNorm normalized name: Jarrow Formulas Extra Virgin Coconut Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virgin coconut oil (VCO) 30 ml per day for four weeks